The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 16th 2025
Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.
Technology Aims to Prevent Drug Diversion
January 30th 2019Recognizing the ongoing opioid crisis and the need to deter theft of drugs, at least 2 medical technology companies—BD and Invistics—have come up with promising digital solutions that track how medications are being dispensed.
Read More
FDA Expands the Use of Ibrutinib to Include Combination for Certain Patients With CLL/SLL
January 28th 2019The FDA has approved the use of ibrutinib (Imbruvica®, AbbVie) in combination with obinutuzumab (Gazyva®) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
FDA Analysis Addresses ARB Impurity Risk to Patients
January 25th 2019Conducted by the FDA, an analysis follows a series of recalls for some generic versions of the angiotensin II receptor blocker (ARB) medicines containing nitrosamine impurities that do not meet the agency’s safety standards.
Read More